InventisBio Co

InventisBio Co FCF/Debt

Free Cash Flow to Debt Ratio of InventisBio Co (688382.SS) as of Nov 20, 2026.

FCF/Debt

-

Last updated:

Free Cash Flow to Debt Ratio of InventisBio Co is 2026 - . Free Cash Flow to Debt Ratio of InventisBio Co was 2025 - . It decreases by % lower compared to the previous year.

Access this data via the Eulerpool API

100,000 free requests/mo · no credit card

InventisBio Co Stock analysis

What does InventisBio Co do? InventisBio Co Ltd, headquartered in Shanghai, China, operates in the Health Care sector within the Biotechnology industry. The company employs 222 full-time staff and completed its IPO on July 25, 2022. InventisBio focuses on drug research and development for major diseases including tumors and metabolic conditions. Its core products under clinical development include D-0120, D-0502, D-1553, and BPI-D0316, targeting oncology and metabolic disease areas. InventisBio Co is one of the most popular companies on Eulerpool.

Frequently Asked Questions about InventisBio Co stock

On Eulerpool you can find the complete historical development of Free Cash Flow to Debt Ratio InventisBio Co since 2006 – with annual values, charts, and detailed analysis.

FCF/Debt measures the percentage of total debt that could be repaid from free cash flow. It is a stricter measure than OCF/Debt as it accounts for capital expenditures.

A 'good' varies by industry and company stage. On Eulerpool, you can compare Free Cash Flow to Debt Ratio's InventisBio Co with sector peers and the industry average to assess whether it is attractive.

Access this data via the Eulerpool API

100,000 free requests/mo · no credit card

Leverage — InventisBio Co

All Key Metrics — InventisBio Co